Carine obtained her PhD in 2002 (Paris XI / Paris-Saclay University) investigating the transcription regulation in S.cerevisiae in the Curie Institute (Orsay). She began her professional career with a series of different contracts: first at INRAE studying the proteasome of B. subtilis, then at the Curie Institute, developing a CGH-array DNA chip to study various murine cancers, under the supervision of Dr Olivier Delattre. At this point, she joined Edith Heard’s team to study the epigenetics of the human X chromosome in various breast tumours, before joining the CNRS in 2006.
After seven years at Chimie ParisTech working on the antibacterial screening platform of the CNRS National Chemical Library network, she joined back the Curie Institute, this time to work on Drosophila (D. melanogaster). First working under the supervision of Dr Jean-René Huynh, then Dr Pierre Léopold, she combined the roles of engineer (ChIP, CRISPR, etc.), team lab manager and Prevention Assistant for the unit until 2022. She then took a three-year contract to work at Génopole in an INSERM laboratory (US45) on the development of new iPS cell lines for therapeutic purposes.
Once her assignment was complete, she joined Dounia DJEGHLOUL’s team in 2025 at the Epigenetics and Cell Fate Centre as an engineer and lab manager.
After seven years at Chimie ParisTech working on the antibacterial screening platform of the CNRS National Chemical Library network, she joined back the Curie Institute, this time to work on Drosophila (D. melanogaster). First working under the supervision of Dr Jean-René Huynh, then Dr Pierre Léopold, she combined the roles of engineer (ChIP, CRISPR, etc.), team lab manager and Prevention Assistant for the unit until 2022. She then took a three-year contract to work at Génopole in an INSERM laboratory (US45) on the development of new iPS cell lines for therapeutic purposes.
Once her assignment was complete, she joined Dounia DJEGHLOUL’s team in 2025 at the Epigenetics and Cell Fate Centre as an engineer and lab manager.